Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: A review of the literature

Clinical Interventions in Aging

Volumn 3, Issue 3, 2008, Pages 483-489

  Iwamoto, Jun ^a   Sato, Yoshihiro ^b   Takeda, Tsuyoshi ^a   Matsumoto, Hideo ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitate Hospital   (Japan)

Author keywords

Bone mineral density; Bone turnover; Cortical porosity; Cortical thickness; Hip fracture

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PLACEBO; RISEDRONIC ACID; VITAMIN D;

BONE DENSITY; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CALCIUM INTAKE; CELL VIABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORTICAL BONE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HUMAN; META ANALYSIS; NONHUMAN; OSTEOCYTE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; RISK REDUCTION; VITAMIN D DEFICIENCY;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; FEMALE; HIP FRACTURES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 54949125932     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Bauer DC, Black DM, Garnero P, et al. 2004. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res, 19:1250-8.
2. Bell KL, Loveridge N, Power J, et al. 1999a. Intracapsular hip fracture: increased cortical remodeling in the thinned and porous anterior region of the femoral neck. Osteoporos Int, 10:248-57.
3. Bell KL, Loveridge N, Power J, et al. 1999b. Regional differences in cortical porosity in the fractured femoral neck. Bone, 24:57-64.
4. Bell KL, Loveridge N, Power J, et al. 1999c. Structure of the femoral neck in hip fracture: cortical bone loss in the inferoanterior to superoposterior axis. J Bone Miner Res, 14:1111-9.
5. Black DM, Cummings SR, Karpf DB, et al. 1996. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet, 348:1535-41.
6. Black DM, Delmas PD, Eastell R, et al. 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 356:1809-22.
7. Black DM, Schwartz AV, Ensrud KE, et al. 2006. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA, 296:2927-38.
8. Boivin GY, Chavassieux PM, Santora AC, et al. 2000. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone, 27:687-94.
9. Bone HG, Hosking D, Devogelaer JP, et al. 2004. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med, 350:1189-99.
10. Bousson V, Bergot C, Meunier A, et al. 2000. CT of the middiaphyseal femur: cortical bone mineral density and relation to porosity. Radiology, 217:179-87.
11. Centre for Evidence-Based Medicine. Oxford-Centre Evidence Based Medicine. Levels of Evidence and Grades of Recommendation. http://www.cebm.net/levels_of_evidence.asp.
12. Cooper C, Atkinson EJ, Jacobsen SJ, et al. 1993. Population-based study of survival after osteoporotic fractures. Am J Epidemiol, 137:1001-5.
13. Cumming RG, Nevitt MC, Cummings SR. 1997. Epidemiology of hip fractures. Epidemiol Rev, 19:244-57.
14. Cummings SR, Black DM, Thompson DE, et al. 1998. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA, 280:2077-82.
15. Delmas PD. 2002. Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone, 30:14-17.
16. Epstein S. 2005. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc, 80:379-88.
17. Epstein S. 2007. Is cortical bone hip? What determines cortical bone properties? Bone, 41(Suppl 1): S3-8.
18. Follet H, Li J, Phipps RJ, et al. 2007. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone, 40:1172-7.
19. Garnero P, Hausherr E, Chapuy MC, et al. 1996. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res, 11:1531-8.
20. Greenspan SL, Beck TJ, Resnick NM, et al. 2005. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J Bone Miner Res, 20:1525-32.
21. Hedlund LR, Gallagher JC. 1989. The effect of age and menopause on bone mineral density of the proximal femur. J Bone Miner Res, 4:639-42.
22. Hochberg MC, Greenspan S, Wasnich RD, et al. 2002. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab, 87:1586-92.
23. Hochberg MC, Thompson DE, Black DM, et al. 2005. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res, 20:971-6.
24. Iwamoto J, Takeda T, Sato Y. 2006. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin, 22:919-28.
25. Iwamoto J, Takeda T, Sato Y. 2007. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis - Usefulness of alendronate and risedronate. Expert Opin Pharmacother, 8:2743-56.
26. Jaglal SB, Weller I, Mamdani M, et al. 2005. Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res, 20:898-905.
27. Kannus P, Niemi S, Parkkari J, et al. 2006. Nationwide decline in incidence of hip fracture. J Bone Miner Res, 21:1836-8.
28. Kendler D, Kung AW, Fuleihan Gel-H, et al. 2004. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas, 48:243-51.
29. Liberman UA, Weiss SR, Broll J, et al. 1995. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med, 333:1437-43.
30. Loveridge N, Power J, Reeve J, et al. 2004. Bone mineralization density and femoral neck fragility. Bone, 35:929-41.
31. McClung MR, Geusens P, Miller PD, et al. 2001. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med, 344:333-40.
32. Melton LJ 3rd, Kanis JA, Johnell O. 2005. Potential impact of osteoporosis treatment on hip fracture trends. J Bone Miner Res, 20:895-7.
33. NIH Consensus Development. 2001. Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA, 285:785-95.
34. Papapoulos SE, Quandt SA, Liberman UA, et al. 2005. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in post-menopausal women. Osteoporos Int, 16:468-74.
35. Rabenda V, Mertens R, Fabri V, et al. 2008. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int, 19:811-18.
36. Rizzoli R, Greenspan SL, Bone G III, et al. 2002. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res, 17:1988-96.
37. Reginster JY, Seeman E, De Vernejoul MC, et al. 2005. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab, 90:2816-22.
38. Roschger P, Rinnerthaler S, Yates J, et al. 2001. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone, 29:185-91.
39. Rossini M, Bianchi G, Di Munno O, et al. 2006. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int, 17:914-21.
40. Rossouw JE, Anderson GL, Prentice RL, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288:321-33.
41. Schnitzer T, Bone HG, Crepaldi G, et al. 2000. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging, 12:1-12.
42. Sclar DA, Chin A, Skaer TL, et al. 1991. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther, 13:489-95.
43. Simon JA, Lewiecki EM, Smith ME, et al. 2002. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study. Clin Ther, 24:1871-86.
44. Siris ES, Harris ST, Rosen CJ, et al. 2006. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc, 81:1013-22.
45. Szulc P, Seeman E, Duboeuf F, et al. 2006. Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women. J Bone Miner Res, 21:1856-63.
46. WHO Scientific Group. 2003. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser, 921:86-109.